Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neratinib + fulvestrant
- Development stage
- Phase 2
- Lead developer
- Puma Biotechnology
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Neratinib + fulvestrant is a combination regimen of two pharmaceutical drugs: neratinib, an oral, irreversible pan-HER tyrosine kinase inhibitor, and fulvestrant, an injectable estrogen receptor antagonist. This combination is being investigated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-mutated, metastatic breast cancer that is HER2 non-amplified. Neratinib targets and inhibits HER2, HER4, and EGFR kinases and is thought to overcome mechanisms of endocrine resistance mediated by HER2 mutations. Fulvestrant binds to estrogen receptors (ER), antagonizes their signaling, and accelerates their degradation, thereby blocking estrogen-driven tumor growth. The combination is intended to target both ER and HER2-driven pathways, potentially improving outcomes for patients with HER2-mutant HR+ breast cancer who have progressed on prior endocrine therapy.
- Brand names
- Nerlynx + Faslodex
- Other names
- neratinib and fulvestrantNerlynx and Faslodex
02
Targets
EGFR (Epidermal growth factor receptor)ESR1 (ERα)ESR2 (ERβ)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on neratinib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neratinib + fulvestrant.